Sermorelin Telehealth in United States (USA)

For most adults considering sermorelin, the first practical question is not pharmacology — it is logistics. The molecule has been clinically familiar since the late 1990s, when Geref carried FDA approval for pediatric growth hormone deficiency diagnostics; what has changed in the past two years is the path a private-pay adult uses to obtain it. That path is now almost entirely telehealth: a written questionnaire, a video consultation with a clinician licensed in the patient’s state of residence, a venous draw at a national lab partner, and a compounded vial shipped from a 503A pharmacy to a residential address. There is no in-person clinic visit, no insurance prior authorization, and no commercial finished-drug equivalent, because Merck Serono discontinued Geref in 2008 for commercial reasons unrelated to safety or efficacy. Compounded sermorelin acetate now fills that supply gap under FDA’s interim 503A bulks list policy, which the agency finalized on January 7, 2025.

The result is a program that looks more like a regulated subscription than a traditional doctor’s office. A typical onboarding takes three to ten business days from form submission to first injection. Pricing is bundled — consultation, compounded medication, syringes, alcohol swabs, sharps container, and a 12-week follow-up lab — and refunded if the clinician determines the patient is not an appropriate candidate. The rest of this page explains what the medication actually does, how the telehealth pathway is structured, what the dosing and lab-monitoring cadence looks like in practice, who should and should not be on it, and how the 503A regulatory framing differs from an FDA-approved finished drug.

Why a pulsatile signal matters

Sermorelin acetate is a synthetic 29-amino-acid peptide identical to the first 29 residues of endogenous growth hormone releasing hormone (GHRH 1-44). That truncated sequence preserves the full biological activity of native GHRH while shortening the half-life to roughly 10 to 20 minutes after subcutaneous injection. When sermorelin reaches the anterior pituitary, it binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor on somatotroph cells. Receptor activation raises intracellular cAMP via Gαs, increases GH gene transcription, and triggers exocytosis of preformed secretory vesicles. The result is a discrete pulse of the patient’s own growth hormone — not exogenous recombinant GH — released over roughly 60 to 90 minutes.

The pulsatile character of that release is not incidental; it is the entire clinical rationale for using a secretagogue rather than recombinant somatropin. Native GH is secreted in roughly 6 to 12 discrete bursts per day, the largest of which occurs in the first hours of slow-wave sleep. Continuous, supraphysiologic GH exposure — the pattern produced by daily injection of recombinant GH at non-replacement doses — desensitizes hepatic GH receptors, dysregulates IGF binding proteins, and predictably produces insulin resistance, fluid retention, and arthralgia. By contrast, a sermorelin-induced pulse rides on top of the pituitary’s existing somatotropin-somatostatin rhythm. Because the hypothalamic-pituitary axis remains intact, two endogenous brakes stay in place: rising IGF-1 feeds back negatively at the pituitary and hypothalamus, and somatostatin tone rises in parallel. That feedback ceiling is why sermorelin has no documented mechanism for sustained supraphysiologic IGF-1 elevation and why acute overdose is pharmacologically difficult — the pituitary simply stops responding once feedback signals saturate.

The four-step telehealth pathway

A compliant sermorelin telehealth program separates cleanly into four stages, and understanding each one explains both the timeline and the cost structure.

The first stage is intake. The patient completes a structured medical history covering current medications, past oncology history, diabetes status and most recent A1c, sleep apnea, pituitary disease, prior anabolic or growth hormone use, and goals. The form also captures state of residence, which determines which clinicians on the network can take the case. A clinician licensed in Texas cannot legally write a prescription for a patient who resides in Vermont, regardless of where the pharmacy ships from. Platforms that operate in all 50 states maintain a roster of physicians, nurse practitioners, and physician assistants whose licenses collectively cover every jurisdiction, plus the District of Columbia. Some clinicians hold compact licenses under the Interstate Medical Licensure Compact, which accelerates multi-state coverage but does not eliminate the per-state requirement.

The second stage is laboratory work. Before any prescription is issued, the program orders a baseline panel that almost always includes IGF-1, a comprehensive metabolic panel, fasting glucose and A1c, a complete blood count, a lipid panel, and TSH with free T4. Many programs also order PSA in men over 40 and a basic morning testosterone, because low-T and low-GH symptom profiles overlap heavily and the wrong axis can be treated by mistake. The order is routed electronically to Quest, Labcorp, or a regional equivalent, and the patient walks into a draw station within a few days. Results return to the clinician, not the patient first.

The third stage is clinical review. The prescribing clinician holds a synchronous audio-visual consultation, confirms the history, reviews the labs, screens for contraindications, and either issues a prescription, requests additional workup, or declines the case. A decline at this stage triggers the program’s medication refund. The clinician also sets the starting dose and the follow-up schedule.

The fourth stage is fulfillment. The prescription is transmitted to a 503A compounding pharmacy that has nominated sermorelin acetate as a bulk drug substance and operates under state board of pharmacy oversight plus USP 797 sterile compounding standards. The pharmacy compounds the lyophilized peptide, packages it with bacteriostatic water for reconstitution, insulin syringes, alcohol prep pads, a sharps container, and written reconstitution instructions, and ships under cold-chain or ambient conditions appropriate to the formulation. Delivery is signature-required to a residential address. Refills follow the same chain on a monthly or quarterly cadence.

Dosing protocol and what shows up on follow-up labs

Adult dosing of compounded sermorelin is well-converged across clinical practice, though it remains off-label. The typical starting dose is 200 to 300 mcg subcutaneously once nightly, injected roughly 30 minutes before sleep onset on an empty stomach. Bedtime timing aligns the induced GH pulse with the natural slow-wave-sleep surge; a recent meal — particularly one with significant carbohydrate — blunts that pulse because postprandial somatostatin tone is elevated. Most programs prescribe a 5-on, 2-off weekly cycle, where the patient skips two non-consecutive nights per week. The clinical rationale is to limit receptor desensitization, since chronic uninterrupted agonism at GHRHR has been associated with attenuated response in long-duration animal studies.

Titration is driven by the 12-week follow-up lab. The single most important downstream marker is IGF-1, because circulating IGF-1 integrates GH activity over roughly 24 hours, whereas serum GH itself is too pulsatile to interpret from a single draw. The clinical target is to move IGF-1 from the lower quartile of the age-adjusted reference range to the upper quartile — not above it. A patient who starts at an IGF-1 of 95 ng/mL and arrives at 180 ng/mL at week 12 has responded as expected; a patient still at 110 ng/mL is a candidate for upward titration to 400 or 500 mcg nightly, contingent on tolerance. Patients whose IGF-1 exceeds the age-adjusted upper limit are dose-reduced regardless of symptoms. Additional follow-up markers include fasting glucose and A1c, because GH antagonizes insulin action at the hepatocyte and a modest rise in fasting glucose is the most common reason to hold or reduce dosing.

Who the program is and isn’t for

Compounded sermorelin is appropriate for generally healthy adults with documented age-related decline in the GH-IGF-1 axis, intact pituitary function, and goals oriented around sleep quality, recovery, body composition, and the metabolic markers above. It is not a substitute for diagnosed adult growth hormone deficiency arising from pituitary pathology — that condition requires endocrinology referral and recombinant somatropin under FDA-approved indications.

The screening declines fall into clear categories. Active malignancy is an absolute contraindication, because GH and IGF-1 are mitogenic and could theoretically accelerate tumor proliferation; a personal cancer history in stable remission requires oncology sign-off. Severe non-proliferative or proliferative diabetic retinopathy is a contraindication because GH worsens retinal microvascular disease. Acute critical illness and the immediate post-surgical window are contraindicated because trials of GH-axis agents in ICU populations have shown increased mortality. Patients with non-functional pituitary anatomy — empty sella, prior hypophysectomy, post-radiation panhypopituitarism — will not respond to a secretagogue because the somatotroph substrate is absent. Pregnancy, breastfeeding, and uncontrolled type 2 diabetes are also disqualifying.

Regulatory framing — 503A and the compounded medication disclosure

The single most important consumer disclosure on this page is that compounded sermorelin is not an FDA-approved finished drug. There is no NDA, no orange book entry, no commercial brand, and no manufacturer-published prescribing information. What exists instead is a 503A regulatory pathway under section 503A of the Federal Food, Drug, and Cosmetic Act, which permits a state-licensed pharmacy to compound a medication for an individually identified patient based on a valid prescription from a licensed practitioner.

Sermorelin acetate sits in Category 1 of the FDA’s interim 503A bulks list, the category for substances that may continue to be compounded while the agency completes substance-by-substance evaluation. The interim policy was finalized in the January 7, 2025 guidance and explicitly preserves Category 1 substances for ongoing compounding by traditional 503A pharmacies and 503B outsourcing facilities. Compounded medications are not generic equivalents; potency, sterility, and excipient profile depend on the individual pharmacy’s USP compliance, which is why programs that operate at scale concentrate orders at a small number of pharmacies with documented inspection histories. Patients should expect their vial to carry a compounding pharmacy label, a beyond-use date rather than an expiration date, and reconstitution instructions specific to that formulation.

If you have read this far and want to see what coverage looks like in your specific market, the regional grids that follow this article let you drill down to your state and to the metro areas where the program currently has clinicians licensed to prescribe. The medicine, the labs, and the pharmacy chain are the same nationwide; only the prescribing clinician is matched to your state of residence.

What sermorelin telehealth costs

Pricing is bundled. The intake, the clinician review, the labs and the medication ship together as a single program. Most plans run between 180 and 240 dollars per month depending on dose and format. HSA and FSA cards are accepted at most partner providers.

Final pricing varies by clinician and pharmacy and is presented before any commitment.